IGF-II Inhibitors
IGF-II inhibitors form a robust class of chemicals designed to directly target the insulin-like growth factor-II (IGF-II) signaling pathway. These inhibitors act on the insulin-like growth factor receptor (IGF-IR) and its related pathways, providing specific tools to dissect and modulate IGF-II-mediated cellular responses. Within this class, Picropodophyllin (PPP) and AG1024 (Tyrphostin) standout as direct IGF-IR tyrosine kinase inhibitors, disrupting IGF-II signaling by blocking receptor phosphorylation. Similarly, NVP-AEW541, PQ401, BMS-754807, OSI-906 (Linsitinib), AXL1717 (Picropodophyllotoxin), NVP-ADW742, NT157, Linsitinib (OSI-906), PPPB, and GSK1838705A exert their effects by inhibiting IGF-IR and insulin receptor (InsR) phosphorylation, providing a comprehensive toolkit for investigating IGF-II-related processes.
These inhibitors play a pivotal role in directly interfering with downstream cascades, attenuating IGF-II-induced mitogenic and anti-apoptotic effects. For instance, OSI-906 disrupts IGF-II signaling by inhibiting the phosphorylation of IGF-IR and InsR, thus interfering with pathways that govern cellular responses to IGF-II. The intricate details of how each inhibitor influences specific biochemical and cellular pathways are crucial for unraveling the intricate regulatory mechanisms of IGF-II. Understanding the specific biochemical and cellular pathways influenced by each inhibitor is crucial for unraveling the intricate regulatory mechanisms of IGF-II. The detailed characterization of this chemical class enhances our ability to manipulate IGF-II-related cellular processes, offering insights into potential avenues for interventions. For instance, OSI-906 disrupts IGF-II signaling by inhibiting the phosphorylation of IGF-IR and InsR, thereby interfering with pathways that govern cellular responses to IGF-II. By elucidating these specific mechanisms, researchers gain valuable tools to manipulate and investigate IGF-II-related cellular processes. In summary, the diverse array of IGF-II inhibitors represents a powerful toolkit for researchers aiming to dissect and modulate the IGF-II signaling pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IGF-1R Inhibitor, PPP | 477-47-4 | sc-204008A sc-204008 sc-204008B | 1 mg 10 mg 100 mg | $138.00 $203.00 $895.00 | 63 | |
PPP inhibits IGF-IR tyrosine kinase, directly impeding the IGF-II signaling pathway. By blocking IGF-IR phosphorylation, PPP disrupts downstream cascades, attenuating IGF-II-induced cellular responses. This action inhibits IGF-II's mitogenic and anti-apoptotic effects, hindering cancer cell proliferation dependent on IGF-II signaling. | ||||||
AG 1024 | 65678-07-1 | sc-205907 | 1 mg | $107.00 | 22 | |
AG1024 targets IGF-IR, acting as a specific tyrosine kinase inhibitor. Its inhibition of IGF-IR phosphorylation disrupts downstream signaling, directly impeding IGF-II-mediated cellular responses. This inhibition attenuates IGF-II-induced mitogenic and survival pathways, providing a direct mechanism to hinder IGF-II signaling. | ||||||
NVP-AEW541 | 475489-16-8 | sc-507395 | 5 mg | $285.00 | ||
NVP-AEW541 inhibits IGF-IR, curtailing IGF-II signaling. By impeding IGF-IR phosphorylation, it directly interferes with downstream pathways, mitigating the mitogenic and anti-apoptotic effects of IGF-II. This targeted inhibition highlights its potential as a specific tool to modulate IGF-II-dependent cellular processes. | ||||||
PQ401 | 196868-63-0 | sc-221738 | 10 mg | $146.00 | ||
PQ401 functions as a selective IGF-IR inhibitor, directly hindering IGF-II signaling. By blocking IGF-IR phosphorylation, PQ401 disrupts downstream pathways, attenuating IGF-II-induced cellular responses. This direct interference with IGF-II signaling establishes PQ401 as a potent inhibitor with implications for understanding and controlling IGF-II-related processes. | ||||||
BMS-754807 | 1001350-96-4 | sc-507396 | 5 mg | $304.00 | ||
BMS-754807, a potent IGF-IR/InsR inhibitor, directly disrupts IGF-II signaling. By inhibiting IGF-IR and insulin receptor (InsR) phosphorylation, it interferes with downstream cascades, mitigating the mitogenic and anti-apoptotic effects induced by IGF-II. This direct inhibition positions BMS-754807 as a valuable tool for investigating and modulating IGF-II responses. | ||||||
Linsitinib | 867160-71-2 | sc-396762 sc-396762A | 5 mg 10 mg | $146.00 $265.00 | 1 | |
Linsitinib, another IGF-IR/InsR inhibitor, directly hampers IGF-II signaling. By inhibiting the phosphorylation of IGF-IR and InsR, OSI-906 disrupts downstream pathways, attenuating IGF-II-induced cellular responses. This direct interference highlights OSI-906 as a specific inhibitor for studying and manipulating IGF-II-related processes. | ||||||
GSK1838705A | 1116235-97-2 | sc-364502 sc-364502A | 5 mg 50 mg | $240.00 $992.00 | ||
GSK1838705A, a dual IGF-IR/InsR inhibitor, directly impedes IGF-II signaling. By inhibiting receptor phosphorylation, it interferes with downstream cascades, mitigating the mitogenic and anti-apoptotic effects induced by IGF-II. This direct inhibition positions GSK1838705A as a versatile tool for investigating and manipulating IGF-II-related processes. | ||||||